Gain detailed insights into the trading activity of Congress members for CCC Intelligent Solutions on our government trades page. Stay updated on how elected officials are investing in CCCS.

CCC Intelligent Solutions - Government Trades

CCC Intelligent Solutions

CCC Intelligent Solutions Holdings Inc is a provider of cloud, mobile, AI, telematics, hyperscale technologies and applications for the property and casualty insurance economy. The company's SaaS platform connects trading partners, facilitates commerce, and supports mission-critical, and AI-enabled digital workflows. The company generate revenue through the sale of software subscriptions and other revenue, primarily from professional services. The company has its presence in United States and China. Majority of the revenue is generated from United States.

Cummins

News

Upgrades

Pre-Market Outlook

Markets

Analyst Ratings

Trading Ideas

CCCS

ONON

PCAR

This Cummins Analyst Turns Bullish; Here Are Top 5 Upgrades For Wednesday

Earnings

Penny Stocks

Small Cap

BYRN

KRUS

MOVE

With U.S. stock futures trading higher this morning on Friday, some of the stocks that may grab investor focus today are as follows:

Kura Sushi, Greenbrier And 3 Stocks To Watch Heading Into Friday

Movers

AFIB

AKTS

AMSC

CISS

COLB

CRGE

EFSH

ONCO

PHUN

SPCB

TSLA

VSME

Shares of  International Business Machines Corporation (NYSE: IBM) shares rose sharply in today’s pre-market trading as the company reported reported stronger-than-expected results for its fourth quarter.

Why IBM Shares Are Trading Higher By Over 7%; Here Are 20 Stocks Moving Premarket

DWAC

NNDM

U.S. stock futures were mostly higher this morning, with the Dow futures gaining around 80 points on Thursday.

Tesla Reports Downbeat Results, Joins Hexcel, Columbia Banking System And Other Big Stocks Moving Lower In Thursday&#39;s Pre-Market Session

Intraday Update

AFRM

Amplify YieldShares Oil Hedged MLP Income ETF

AMLX

ASLE

ASRT

ASTR

ATRA

BILL

Bakkt Holdings, Inc. Class A Common Stock

BKKT

CART

Cardio Diagnostics Holdings Inc. - Common stock

CDIO

CDLX

CFRX

CIFR

CLMT

COOK

DNUT

FOSL

FREY

GDRX

HNST

HTCR

IKNA

Intelligent Bio Solutions Inc. - Common Stock

INBS

INFN

INSE

JRVR

LAZR

MARA

MODG

MYGN

NVTA

PAHC

PUBM

RAMP

RIOT

RMCO

RVNC

SLGC

SNES

SPCE

TAST

Tempest Therapeutics, Inc. - Common Stock

TPST

WLDS

Gainers


	Intelligent Bio Solutions Inc. (NASDAQ: INBS) shares climbed 83.5% to $0.4169 after reporting first-quarter results.


Why AMC Entertainment Shares Are Trading Lower By Around 14%? Here Are Other Stocks Moving In Thursday&#39;s Mid-Day Session

APPS

FVRR

U.S. stock futures traded mostly higher this morning on Thursday. Here are some big stocks recording losses in today’s pre-market trading session.

AerSale, Topgolf Callaway Brands, Digital Turbine And Other Big Stocks Moving Lower In Thursday&#39;s Pre-Market Session

BGNE

CLOV

LICY

LILM

OPEN

PRME

RYAAY

ZLAB

U.S. stock futures traded higher this morning on Monday. Here are some big stocks recording gains in today’s pre-market trading session.

Ryanair Holdings, Prime Medicine And Other Big Stocks Moving Higher In Monday&#39;s Pre-Market Session

AEHL

APCX

APTX

BBAI

BBBY

BDTX

BPTS

BTBD

CLSN

CNDT

CUEN

EURN

FCUV

FEDU

GWGH

HOWL

HTGM

IMTE

INKT

IRNT

IVDA

MACK

MDVL

MNTS

MOXC

NRSN

NUTX

PHAS

PLSE

SBFM

SEED

STRC

TANH

TRVI

VAPO

VERY

VNET

Gainers


	MedAvail Holdings, Inc. (NASDAQ: MDVL) shares surged 64.4% to close at $1.41 on Thursday. Ally Bridge Group reported a purchase of 21.176 million shares of MedAvail Holdings for an average price of $1.06 per share.


53 Biggest Movers From Yesterday

Gainers


	MedAvail Holdings, Inc. (NASDAQ: MDVL) jumped 57.6% to $1.3515. Ally Bridge Group reported a purchase of 21.176 million shares of MedAvail Holdings for an average price of $1.06 per share.


38 Stocks Moving In Thursday&#39;s Mid-Day Session

ERYP

GNUS

HOUR

LEDS

RNAZ

TKLF

RVPH

Gainers


	HTG Molecular Diagnostics, Inc.  (NASDAQ: HTGM) rose 46.7% to $1.88 in pre-market trading after the company announced it has harmonized its miRNA Whole Transcriptome Assay with the HTG Transcriptome Panel.


23 Stocks Moving in Thursday&#39;s Pre-Market Session

CCC Intelligent Solutions Holdings Inc. - Common Stock

CCC Intelligent Solutions Holdings Inc

Paragon 28 has announced net revenue for the full year of 2024 to be in a range of $255.9 to $256.2 million, representing 18.2% to 18.4% reported growth over the prior fiscal year.&nbsp;
Zimmer Biomet expects the proposed transaction, considering the impact of financing, to be approximately 3% dilutive to adjusted earnings per share in 2025, about 1% dilutive to 2026 adjusted earnings per share and accretive to adjusted earnings per share within 24 months of deal close.
Zimmer Biomet plans to fund the proposed transaction through a combination of cash on the balance sheet and other available debt financing sources. Zimmer Biomet expects to maintain a strong balance sheet and to continue to support its stated capital allocation priorities.

Zimmer Biomet Expects Proposed Paragon 28 Transaction To Immediately Accelerate Revenue Growth And To Be Approximately 3% Dilutive To Adjusted EPS In 2025

Paragon 28 shareholders will also receive a non-tradeable contingent value right (CVR) entitling the holder to receive up to $1.00 per share in cash if certain revenue milestones are achieved.&nbsp;
The CVR will be payable in whole or in part if net sales exceed $346 million up to $361 million (with the CVR payments calculated linearly between $0.00 and $1.00 if net sales are between $346 million and $361 million) during Zimmer Biomet's fiscal year 2026.&nbsp;
The board of directors of each of Zimmer Biomet and Paragon 28 has unanimously approved the proposed transaction.
 &nbsp;

Zimmer Biomet To Acquire Paragon 28 For Upfront Payment Of $13.00 Per Share In Cash, Corresponding To An Equity Value Of $1.1B And Enterprise Value Of $1.2B

Jones Trading analyst Soumit Roy initiates coverage on OnKure Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OKUR#NASDAQ">OKUR</a>) with a Buy rating and announces Price Target of $32.

Price Target

Initiation

OKUR

Jones Trading Initiates Coverage On OnKure Therapeutics with Buy Rating, Announces Price Target of $32

Jefferies analyst Rob Dickerson maintains WK Kellogg (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KLG#NYSE">KLG</a>) with a Hold and lowers the price target from $19 to $16.

Jefferies Maintains Hold on WK Kellogg, Lowers Price Target to $16

The Food and Drug Administration on Tuesday approved Ozempic, the weight loss drug made by Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>), for the treatment of chronic kidney disease in patients who also <a href="https://www.benzinga.com/25/01/42875977/novo-nordisk-seeks-to-strengthen-its-obesity-pipeline-with-back-to-back-two-biobuck-deals">have type 2 diabetes. </a>
The Details: According to the Centers for Disease Control and Prevention, more than 35.5 million Americans have chronic kidney disease, often as a complication of type 2 diabetes. The new FDA approval allows for further expansion of Ozempic's use and potential coverage by health insurance plans.&nbsp;
Read Next:<a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/01/43254018/sofi-stock-falls-on-soft-guidance-despite-strong-quarter-with-record-member-growth-loan-originations-analyst"> SoFi Stock Falls On Soft Guidance Despite &#8216;Strong Quarter&#8217; With Record Member Growth, Loan Originations: Analyst&nbsp;</a>
The FDA approval "allows us to more broadly address conditions within cardiovascular-kidney-metabolic syndrome, which affects millions of adults and could have serious consequences if left untreated," Anna Windle, a senior vice president at Novo Nordisk, said in a statement Tuesday, per a Bloomberg <a href="https://www.bloomberg.com/news/articles/2025-01-28/novo-s-ozempic-notches-approval-for-kidney-disease-widening-use?sref=TBDibEcD">report</a>.&nbsp;
Ozempic and other diabetes drugs known as GLP-1s have become popular and also well-known for their high cost.&nbsp;
Earlier in January, Novo Nordisk's diabetes and weight loss drugs, Ozempic, Rybelsus, and Wegovy were all added to the U.S. Department of Health and Human Services list of drugs covered under Medicare Part D that<a href="https://www.benzinga.com/25/01/43062779/popular-ozempic-wegovy-selected-for-next-round-of-medicare-drug-price-negotiations"> have been selected</a> for mandated price negotiations in order to reduce <a href="https://www.benzinga.com/general/biotech/24/08/40534249/novo-nordisks-ozempic-might-be-among-2027-medicare-price-negotiation-targets">prescription drug costs</a>.
The negotiations will take place in 2025, with the new prices slated to take effect in 2027.
NVO Price Action: According to <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, Novo Nordisk shares ended Tuesday's session down 2.65% at $85.19.&nbsp;
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/25/01/43287988/microsoft-q2-preview">Microsoft Q2 Earnings Preview: Street &#8216;Too Optimistic&#8217; On Near-Term AI Returns?&nbsp;</a></li>
</ul>
Photo: Shutterstock

Biotech

Health Care

General

Ozempic Receives FDA Approval To Treat Kidney Disease

Trading Halt: Halt status updated at 5:50:00 PM ET: Quotation Resumption: News and Resumption Times

Finward Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FNWD#NASDAQ">FNWD</a>) reported quarterly earnings of $0.49 per share which beat the analyst consensus estimate of $0.20 by 145 percent. This is a 40 percent increase over earnings of $0.35 per share from the same period last year. The company reported quarterly sales of $16.34 million which beat the analyst consensus estimate of $16.00 million by 2.12 percent. This is a 5.75 percent increase over sales of $15.45 million the same period last year.

Earnings Beats

FNWD

Finward Bancorp Q4 2024 GAAP EPS $0.49 Beats $0.20 Estimate, Sales $16.34M Beat $16.00M Estimate

Compass Point analyst Giuliano Bologna upgrades Affirm Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AFRM#NASDAQ">AFRM</a>) from Sell to Neutral and raises the price target from $20 to $61.

Compass Point Upgrades Affirm Holdings to Neutral, Raises Price Target to $61

The options include a possible sale of the company, business combination, sale of all or part of the Company's assets, licensing of assets, restructuring, or other strategic action.

23andMe Reveals Process To Explore Strategic Alternatives

Compass Point analyst Joe Flynn initiates coverage on Applied Digital (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APLD#NASDAQ">APLD</a>) with a Buy rating and announces Price Target of $10.

APLD

Compass Point Initiates Coverage On Applied Digital with Buy Rating, Announces Price Target of $10

Synaptics Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SYNA#NASDAQ">SYNA</a>) shares are rising in extended trading Tuesday after the company signed a <a href="https://www.benzinga.com/pressreleases/25/01/g43286953/synaptics-accelerates-edge-ai-strategy-with-new-broadcom-agreement">licensing agreement with Broadcom Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVGO#NASDAQ">AVGO</a>)</a>.
What Happened: After the market close on Tuesday, Synaptics announced it&#8217;s accelerating its Edge <a href="http://benzinga.com/topic/ai">AI</a> strategy through a definitive licensing agreement with Broadcom.
The agreement includes Wi-Fi&nbsp;8, ultra-wideband (UWB), Wi-Fi 7, advanced Bluetooth and GPS/GNSS products and technology for IoT and the Android ecosystem.
&#8220;Our wireless technology and capabilities are cornerstones of our success in IoT markets,&#8221; said Michael Hurlston, president and CEO of Synaptics. 
&#8220;We are now developing this expertise to enable ecosystems with centralized control and seamless connectivity to a rapidly growing array of Edge AI devices. Our platform history, proven track record, and strategy uniquely position us to integrate Broadcom&#8217;s technology and fully deliver on the potential of IoT connectivity.&#8221;
Check This Out: <a href="https://www.benzinga.com/general/restaurants/25/01/43288533/starbucks-q1-earnings-revenue-beat-eps-beat-memberships-up-1-positive-response-to-turnaround-efforts">Starbucks Q1 Earnings: Revenue Beat, EPS Beat, Memberships Up 1%, &#8216;Positive Response&#8217; To Turnaround Efforts</a>
Synaptics said the deal is expected to add&nbsp;at least $40 million in annualized sales. The company also expects the transaction to be immediately accretive to adjusted earnings per share. 
The all-cash transaction is expected to close on Jan. 30. Financing details were not provided, but Synaptics said it will provide more information on the transaction when it reports <a href="https://www.benzinga.com/calendars/earnings">second-quarter earnings</a> on Feb. 6. 
Analysts currently expect Synaptics to report earnings of 86 cents per share and revenue of $265.14 million for the second quarter, according to <a href="http://pro.benzinga.com">Benzinga Pro</a> estimates.
SYNA Price Action: Synaptics shares were up 5.13% in after-hours, trading at $84.66 at the time of publication Tuesday, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
This illustration was generated using artificial intelligence via Midjourney.

Contracts

After-Hours Center

Tech

AVGO

SYNA

Synaptics Stock Climbs On Broadcom Deal Focused On Edge AI

MGNI

Magnite Says Working With Sky New Zealand To Power Programmatic Advertising On Sports Streaming Platform, Sky Sport Now

Compass Point analyst David Rochester downgrades Synchrony Finl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SYF#NYSE">SYF</a>) from Buy to Neutral and announces $70 price target.

Downgrades

Compass Point Downgrades Synchrony Finl to Neutral, Announces $70 Price Target

Through this contract, Planet joins the Copernicus Contributing Missions, officially contributing commercial satellite data alongside ESA's Sentinel satellite data to the Copernicus services.

Planet Labs Germany GmbH Signs Multi-year Contract With The European Space Agency

Government Trades

CCC Intelligent Solutions Holdings Inc

top performing CCCS trades

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga